Accueil>>Signaling Pathways>> Endocrinology and Hormones>> Thyroid hormone Receptor>>TR antagonist 1

TR antagonist 1

Catalog No.GC31402

L'antagoniste TR 1 est un antagoniste des récepteurs de l'hormone thyroÏdienne (TR) de haute affinité avec des CI50 de 36 et 22 nM pour TRα et TRβ, respectivement.

Products are for research use only. Not for human use. We do not sell to patients.

TR antagonist 1 Chemical Structure

Cas No.: 500794-88-7

Taille Prix Stock Qté
5mg
495,00 $US
En stock
10mg
765,00 $US
En stock
50mg
2 295,00 $US
En stock
100mg
3 555,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

TR antagonist 1 is a high-affinity thyroid hormone receptor (TR) antagonist with IC50s of 36 and 22 nM for TRα and TRβ, respectively.

TR antagonist 1 displays high affinity for both thyroid hormone TRα and TRβ (IC50=36 and 22 nM, respectively). TR antagonist 1 acts as a full antagonist in the TRAFR cell assay and the IC50 32 nM for both TRAFα1 and TRAFβ1[1].

TR antagonist 1 treatment lowers heart rate and shows a possible trend toward an increase of low-density lipoprotein cholesterol (LDL-C) in the cholesterol fed rat model[1].

[1]. Koehler K, et al. Thyroid receptor ligands. 6. A high affinity "direct antagonist" selective for the thyroid hormone receptor. J Med Chem. 2006 Nov 16;49(23):6635-7.

Avis

Review for TR antagonist 1

Average Rating: 5 ★★★★★ (Based on Reviews and 36 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for TR antagonist 1

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.